-
Heavy! Lilly's new breast ® (Abesili tablets) approved in China!
Time of Update: 2021-01-30
Lilly Pharmaceuticals recently announced that its new anti-tumor drug ® (Abesili tablets) was approved by the State Drug Administration (NMPA) on December 29, 2020 for hormone-positive hormone (HR), human skin growth factor 2 (HER2) negative local late stage or metastatic breast cancer: (1) in combined with aromatase inhibitors as an initial endocrine treatment in post-menstrual female patients.
-
BRCA1/2 mutation platinum-sensitive relapsed ovarian cancer: Olapali is more effective at improving PFS than non-platinum chemotherapy
Time of Update: 2021-01-30
In patients with ovarian cancer with BRCA mutations, platinum-sensitive relapses, and at least second-line platinum-based chemotherapy, improvements in Orapali's objective remission rate (ORR) and non-progressive lifetime (PFS) were both statistically significant and clinically significant compared to non-platinum chemotherapy, according to a Phase III trial reported by Massachusetts General Hospital Penson.
-
Relapsed ovarian cancer: Rucaparib maintains therapeutic advantage analysis
Time of Update: 2021-01-30
≥ level 3 adverse events in treatment defined TOX, the difference between ITT queue, BRCA mutation queue, HRD queue, and BRCA wild type / low LOH patient subgroup Q-TWiST (Rucaparib vs.
-
JAMA oncology: "God medicine" aspirin again, age is very elegant?
Time of Update: 2021-01-30
For example, a CAPP2 study, also published in Lancet last June, found that taking aspirin in early adulthood (average age 45) halved the risk of colorectal cancer in high-risk populations with genetic predispositions, and that the prevention effect lasted for up to 10-20 years!
-
NEJM: HPV vaccination and risk of cervical cancer
Time of Update: 2021-01-30
Methods The following follow-up to the Swedish National Population and Health Register surveyed 1672,983 women aged 10 to 30 between 2006 and 2017 to assess the relationship between HPV vaccination and risk of insulated cervical cancer, and to intervene in controlling factors such as age, age, place of residence, parental characteristics (including education, family income, mother's country of birth, and history of disease).
-
Double PFS, ORR, 40% lower risk of death! FDA approves Cabotinib's joint Opdivo first-line treatment for kidney cancer
Time of Update: 2021-01-30
Last August, Exelixis submitted a listing application to the FDA for Cabotinib's combined Navuliyu single-anti-first-line treatment of late-stage RCC, which was reviewed by the FDA using Real-Time Review of Oncology Drugs (PTOR) and Fast Track, a month ahead of the February 20 PDUFA scheduled date.
-
The French National Gynaecological and Obstetrics and Gynaecology Hospital (CNGOF) guidelines for ovarian junction oncology (2020, lower part) || Surgery, follow-up, hormone replacement therapy, fertility protection and management
Time of Update: 2021-01-30
Abstract: For early junction ovarian tumors (ES BOTs), no risk of tumor rupture surgery is feasible, laparoscopic surgery using sealed bag is better than abdominal surgery (C-grade), early two-sided s
-
Recreational physical activity can significantly improve endometrial cancer survival and prognosis
Time of Update: 2021-01-30
doi:10.1200/JCO.20.01336）。 The purpose of this study was to assess the association between physical activity and survival of endometrial cancer survivors before and after diagnosis by the range, intensity, degree (metabolic equivalent of MET-time/week/year) and changes from pre-diagnosis to post-diagnosis.
-
Sci Tran Med: CAR-T New Switch - Tonadamine | The latest results in the journal Science
Time of Update: 2021-01-30
Because these engineered T-cells continue to make CAR proteins, new CAR proteins accumulate and T-cell anti-tumor function is restored after the amine treatment, and in the ON switch structure, researchers designed a amine-induced djubial system to develop a CAR that needs to be activated at the same time as the amine and target antigen.
-
The opening of the World Lung Cancer Congress is Professor Wu Yilong: Lung cancer slow disease and long survival is not far away
Time of Update: 2021-01-30
recent years, the survival and quality of life of patients with advanced lung cancer have improved significantly, thanks to advances in treatment methods, particularly with the approval of innovative therapies such as targeted and immunotherapy.
-
2020 European Society of Gynaecological Oncology (ESGO) advanced ovarian cancer surgical quality indicators updated
Time of Update: 2021-01-30
QIs are internal validation criteria based on evidence-based research, multidisciplinary international development team meetings, goals and scoring systems, and involve an external review process for doctors and patients.
-
J Clin Oncol: The five-year follow-up prognostic prognostication of the late NSCLC of the Navu single anti-treatment is still significantly better than the Dorset game!
Time of Update: 2021-01-29
In two Phase III trials (CheckMate 017 and CheckMate 057), Navu monoantigens further improved the overall survival rate (OS) of previously treated patients with advanced and non-scaly NSCLC, and were also more safe than dositan.
-
Clin Cancer Res: CEACAM7 is an effective target for CAR-T cells in the treatment of pancreatic catheter adenocarcinoma
Time of Update: 2021-01-29
, the study showed that CEACAM7 was identified as a potential therapeutic target for PDAC, and that CAR T cells targeted at CEACAM7 were constructed and its anti-PDAC efficacy was verified.
-
Ann Surg: 5-year survival rate for patients with advanced esophageal cancer treated with minimally invasive esophageal excision vs open thoracic esophageal excision
Time of Update: 2021-01-29
study aims to compare the five-year survival rates of patients with esophageal cancer after surgery.
compared to OE, MIE is associated with an 18% reduction in 5-year all-cause mortality (correction risk ratio of 0.82, 95% CI 0.67-1.00; P=0.048).
-
Cancer: Can oral bacteria increase the risk of esophageal cancer?
Time of Update: 2021-01-29
In the study, researchers collected plaque and saliva samples from 61 patients with esophageal cancer and 62 healthy controls, using real-time polymerase chain reaction techniques to assess the abundance of common oral bacterial periodontogenic pathogens, including lysozyme, Kercobacteria, gum pyridobacteria, intermediate Prevo bacteria, Forsythtana bacteria, fouling helix and streptococcus.
-
Br J Cancer: Systemic inflammation scores are associated with survival prognosis in patients with brain metastasis tumors
Time of Update: 2021-01-29
systemic inflammatory scores, including the ratio of neutral granulocytes to lymphocytes (NLR), white blood cells to lymphocytes (LLR), plate plate and lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and C-reactive protein/albumin ratio (CRP/Alb) have been shown to affect tumor control and ultimately the survival prognosis of patients with extracranial metastatic cancer.
-
The boom in small molecule RNA targeted therapies is on the way, with pharmaceutical giants around the world flocking to the market
Time of Update: 2021-01-29
biotech-pharma alliance for the development of small molecule drugs targeting RNA Source: Nature Biotechnology last April, Roche struck a massive deal with Arrakis Therapeutics covering all of Roche's research and development areas.
-
New cell therapy! The FDA grants the same allogeneic active degeneration degeneration cell iixadencel orphan drug qualification for the treatment of soft tissue sarcoma (STS)!
Time of Update: 2021-01-29
Dr. Sven Rohmann, chief executive of immunicum, said, "We continue to build recognition of the potential of iixadencel and are pleased to announce that, in addition to our qualifications in Renal Cell Carcinoma (RCC) and Hepatocellular Carcinoma (HCC), we have now received FDA-granted orphan drug eligibility for the treatment of soft tissue sarcoma, including GIST.
-
FDA approves Opdivo in joint Cabometyx for the treatment of advanced renal cell carcinoma
Time of Update: 2021-01-29
The U.S. Food and Drug Administration (FDA) said recently that it has approved a joint first-line treatment for patients with advanced renal cell carcinoma (RCC) using the anti-PD-1 antibody Opdivo (nivolumab) and Exelixis' tyrosine kinase inhibitor Cabozantinib.
-
J Hepatol: Hepatic cell NRF2 specific activation regulates the occurrence of liver fibrosis and liver cancer
Time of Update: 2021-01-29
In fatty liver mice, oxidation should surge and be strongly associated with NRF2 target gene activation in mice, microarray analysis showed that the absence of Keap1 induced NRF2 target genes to participate in glutathione metabolism and heterogeneity stress (e.g., Nqo1).
